Reliance subsidiary Karkinos crosses 1 lakh HPV DNA tests milestone
RELIANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Karkinos Healthcare, Reliance's 100% step-down subsidiary, has completed HPV DNA screening for over 1 lakh women across India, marking a key milestone in cervical cancer prevention. The platform uses WHO-recommended HPV DNA testing with a digitally enabled care continuum covering screening, tracking, triage, navigation, and follow-up. Achieved through public-private partnerships, CSR programmes, nurse-assisted and self-sampling models, and outreach in underserved districts. Karkinos has set a next target of 1 million tests, with a long-term goal of 100 million.
Positive PR for Reliance's healthcare push. Showcases Karkinos subsidiary's scale in oncology and women's health. No immediate direct financial impact.